Clinical Starter Packs

Curated starting points for high-yield specialties

Each pack brings together a key guideline, a current trial, a Drug Science explainer, and a relevant education item so clinicians can get oriented fast.

6 specialties 4 content pillars per pack Open clinical learning

Starter Packs

Use these as orientation pages for a topic area, then continue into the full specialty hub, Trial Radar, Drug Science and education library.

Diabetes / Metabolic

Key Guideline

2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease

This EASD guideline addresses 2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease in Diabetes / Metabolic.

View guideline →

Trial Radar

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ – CVOT)

Survodutide injection reduces cardiovascular events in overweight or obese adults with heart or kidney disease compared to placebo.

View trial →

Drug Science

HMG-CoA Reductase — Statins

HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer.

Open explainer →

Education

NICE NG28: Type 2 Diabetes in Adults — 2024 Update

Apply NICE NG28 updates to type 2 diabetes treatment sequencing, including when SGLT2 inhibitors or GLP-1 receptor agonists should be…

Start learning →

📰

Latest Clinical Brief Daily pill to help keep weight off after stopping obesity jabs

Explore specialty hub Follow this specialty

Cardiology / Cardiovascular

Key Guideline

Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment

AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays…

View guideline →

Trial Radar

Mechanism of Chronic Pain in Patients With IBD

Abdominal pain is a common symptom in patients with inflammatory bowel disease (IBD). Up to 70 % of IBD patients…

View trial →

Drug Science

HMG-CoA Reductase — Statins

HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer.

Open explainer →

Education

Cardiovascular Risk Reduction — Latest Evidence 2024

Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification.

Start learning →

📰

Latest Clinical Brief The struggle to get hold of medication in England is set to get worse

Explore specialty hub Follow this specialty

Respiratory / COPD / Asthma

Key Guideline

UK Achondroplasia Network’s consensus guideline for multidisciplinary care of children and young people with achondroplasia: NICE review

Establish multidisciplinary team review at diagnosis and at key developmental stages (infancy, pre-school, school age, adolescence) to monitor for complications…

View guideline →

Trial Radar

The CATALINA Study

The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported…

View trial →

Drug Science

CFTR Modulation

CFTR Modulation is a clinically relevant Drug Science explainer.

Open explainer →

Education

NICE NG185: COVID-19 Rapid Guideline — Long-term Effects

Distinguish ongoing symptomatic COVID-19 from post-COVID-19 syndrome using NICE NG185 definitions.

Start learning →

📰

Latest Clinical Brief Why illegal children’s homes are being paid up to £2m per child by councils

Explore specialty hub Follow this specialty

Oncology

Key Guideline

Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

Osimertinib is recommended by NICE for EGFR mutation-positive unresectable locally advanced NSCLC only after prior platinum-based chemoradiotherapy has been completed,…

View guideline →

Trial Radar

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Adding CGT9486 to sunitinib compared to sunitinib alone for gastrointestinal stromal tumour patients who've failed or are intolerant to imatinib.

View trial →

Drug Science

BRAF/MEK Pathway — Melanoma

BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer.

Open explainer →

Education

Coming into focus

We’re still building this layer for Oncology.

📰

Latest Clinical Brief Riskiest skin cancer cases hit UK record high

Explore specialty hub Follow this specialty

Rheumatology

Key Guideline

2023 EULAR Recommendations for Systemic Lupus Erythematosus

This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology.

View guideline →

Trial Radar

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn’s Disease or Ulcerative Colitis (MK-7240-011)

Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed…

View trial →

Drug Science

IL-6 Signalling

IL-6 Signalling is a clinically relevant Drug Science explainer.

Open explainer →

Education

JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance

Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease.

Watch webinar →

Explore specialty hub Follow this specialty

Infectious Disease

Key Guideline

Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula

Consider transvenous embolisation in patients with spontaneous intracranial hypotension confirmed to have a cerebrospinal fluid–venous fistula, as it offers a…

View guideline →

Trial Radar